Paper Details

  1. Home
  2. Paper Details

Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis.

Author: GargAmit X, KimRichard B, McArthurEric, SarmaSisira, SchwarzUte I, SituMichael, ZouGuangyong

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Oral anticoagulants (OACs) are used to prevent blood clots in patients with atrial fibrillation (AF). This article discusses the different types of OACs available, including warfarin, rivaroxaban, and apixaban, and compares their cost-effectiveness.
Paper Details　
Original Abstract of the Article :
Non-valvular atrial fibrillation (AF) is a common heart arrhythmia in the elderly population. AF patients are at high-risk of ischemic strokes, but oral anticoagulant (OAC) therapy reduces such risks. Warfarin had been the standard OAC for AF patients, however its effectiveness is highly variable an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10198-023-01594-7

データ提供：米国国立医学図書館（NLM）

Apixaban or Rivaroxaban vs. Warfarin: A Camel's Quest for Cost-Effective Atrial Fibrillation Management

Atrial fibrillation (AF), a common heart rhythm disorder, is like a turbulent sandstorm in the heart, disrupting its normal rhythm. This research delves into the cost-effectiveness of newer oral anticoagulants (OACs), apixaban and rivaroxaban, compared to the traditional warfarin for AF management. The study explores the potential cost savings from the healthcare system perspective. While the newer OACs offer advantages such as greater consistency and reduced monitoring requirements, they are also more expensive. The researchers aim to determine whether these advantages translate into cost savings for the healthcare system.

Navigating the Cost-Effectiveness Landscape: A Camel's Perspective

This study highlights the ongoing efforts to optimize AF management, seeking a balance between efficacy, safety, and cost-effectiveness. The quest for more effective and affordable treatment options for AF is like searching for a well-trodden path through a vast and unforgiving desert.

A Camel's Advice for AF Management

The choice of OAC for AF management is a critical decision, akin to selecting the appropriate gear for a long desert journey. Consulting with a healthcare professional to assess individual needs and weigh the benefits and risks of each option is essential. Remember, prevention is key, just like ensuring a well-stocked caravan before embarking on a long journey.

Dr.Camel's Conclusion

This research explores the cost-effectiveness of newer OACs in managing AF, a condition affecting millions worldwide. Finding the optimal balance between efficacy, safety, and cost is an ongoing journey. Understanding individual needs and consulting with a healthcare professional to make informed decisions are crucial steps in navigating this complex landscape.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-05-17
Further Info :

Pubmed ID

37195343

DOI: Digital Object Identifier

10.1007/s10198-023-01594-7

Related Literature

Article Analysis
・Effects of apixaban・Effects of rivaroxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.